Biotech Business – October 6, 2026
Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.
Global report – October 6, 2026
AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company’s workforce in the state by more than 50%.
Clinical Trials – October 6, 2026
Boehringer Ingelheim’s survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.
Pharma Business – October 6, 2026
The US FDA has extended its review of Novo’s Biologics License Application for denecimig in haemophilia A, citing ongoing remediation work at a manufacturing facility. No new timeline for a decision has been communicated.
Events – October 5, 2026
As an NLS Member, you and your colleagues get discounted tickets to selected life science events. This fall, members can save on Health Design in Finland, FHIM in China, and BIO-Europe in Germany.
Science Award – October 5, 2026
The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.
Clinical Trials – October 6, 2026
Boehringer Ingelheim’s survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.
Clinical Trials – October 6, 2026
Lundbeck has randomized the first patient in the Phase II DARE2 trial of its oral Parkinson’s candidate Lu AF28996. In an interview with NLS, Tarek Samad, Head of R&D, explains what the trial needs to show to justify Phase III and where the drug could fit alongside existing treatments.
Clinical Trials – October 5, 2026
Genmab has reported Phase 2 results for its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 treated patients.
Clinical Trials – October 3, 2026
Lundbeck has reported headline results from the Phase IV THRIVE trial, in which 60% of migraine patients who had responded inadequately to a prior CGRP-targeting preventive therapy reported being “much” or “very much” improved after 24 weeks on Vyepti (eptinezumab).
Clinical Trials – October 2, 2026
Stockholm-based Atrogi has reported positive human data for ATR-258, its first-in-class oral therapy designed to improve muscle function and body composition. Over eight weeks, treatment was associated with an approximately 13% improvement in lower-extremity muscle power, together with more lean mass and less fat mass.
Clinical Trials – October 2, 2026
Stockholm-based Mendus has presented updated five-year follow-up data from its completed ADVANCE II trial in acute myeloid leukemia (AML). It also gave an update on the ongoing VITAL-CML trial of its immunotherapy vididencel in chronic myeloid leukemia (CML). The data were presented at the Second Bologna Workshop on Immunotherapy for AML in Italy.
PharmaRelations
Are you a people-oriented Quality Assurance professional with a passion for business development, customer relationships and building successful teams?
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
PharmaRelations
PharmaRelations is the Nordic market leader within talent services for the life science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region. We add value to our clients and candidates with our consultancy services, outsourcing solutions and recruitment of specialists and leaders.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
Stillingen er 100 % remote med en forventet arbejdsbelastning på ca. 0-20 timer pr. måned, afhængigt af projektbehov.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
In a new job – October 5, 2026
Alligator Bioscience has appointed its CFO, Johan Giléus, as CEO, effective January 1, 2027. He succeeds Søren Bregenholt, who will remain in the role until the end of the year.
In a new job – September 21, 2026
Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.
In a new job – September 17, 2026
Over the course of her career, Anna Sundin has worked on numerous transactions spanning capital raises, IPOs, M&A, and debt financing, as well as providing strategic advice to companies in a growth phase.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Profiles in Business – September 30, 2026
Trine Bartholdy has spent her career at the intersection of science and finance, helping early discoveries grow into companies capable of shaping the future of health. Now, as AI and global competition are reshaping the conditions for European life sciences, she and her colleagues at the BioInnovation Institute (BII) leverage decades of expertise to usher young Nordic companies toward entrepreneurial success.
Profiles in Business – September 24, 2026
As HealthCap marks 30 years of life science investing, co-founder Björn Odlander reflects on the firm’s long-term approach, the journey from lab to patient, and Europe’s widening capital gap.
Pharma Business – October 1, 2026
Novo has cut the price of its obesity drug Wegovy in Sweden by 20%, effective October 1. Patients currently pay for the treatment out of pocket, and the company says the cut is meant to help more people stay on treatment over time.
Financing – September 30, 2026
Danish biotech Breye Therapeutics has closed an oversubscribed EUR 67.5 million Series A financing to advance danegaptide, its first-in-class oral treatment for non-proliferative diabetic retinopathy (NPDR), into a Phase II clinical trial.
New Market – September 29, 2026
Egetis Therapeutics has received FDA approval for Emcitate (tiratricol), making it the first approved treatment in the US for patients with the rare genetic disease MCT8 deficiency. With the approval, the company also received a Rare Pediatric Disease Priority Review Voucher.
Collaboration – October 5, 2026
FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica’s surgical microscope systems.
Financing – October 1, 2026
Umeå-based biotech Omnio has raised EUR 2.9 million in an oversubscribed round from existing investors and shareholders. The funding will move the company’s plasminogen-based therapy for hard-to-heal chronic wounds closer to clinical trials, with patient studies planned for 2027.
MedTech Business – September 30, 2026
The company has signed a new contract with a leading US hospital network that operates multiple hospitals in the eastern United States. The contract covers an initial installation of 60 next-generation TetraGraph systems for monitoring patients under anaesthesia.
Biotech article – October 1, 2026
Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.
Biotech Business – October 1, 2026
Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle’s AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.
Biotech Business – September 24, 2026
Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.
Science Award – October 2, 2026
It is once again time to honor extraordinary scientific discoveries. Will it be the GLP-1 pioneers – among them Denmark’s Jens Juul Holst – optical coherence tomography, the wakefulness peptide orexin, or precision gene editing that is honored this year? Or will it be something completely different?
Science News – October 2, 2026
Karolinska Institutet’s Center for Systems Infection Biology (CSIB) is being inaugurated today, October 2, at Campus Flemingsberg.
Science News – September 28, 2026
SciLifeLab is increasing its space on Campus Solna by more than 9,000m². Property owner Akademiska Hus is investing approximately SEK 230 million in an extensive renovation that will give the research center more modern laboratories, flexible workspaces, and new facilities for meetings and training.
This site uses cookies
